Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Cytokine ; 172: 156413, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37918054

RESUMEN

Given the clinical success of cytokine blockade in managing diverse inflammatory human conditions, this approach could be exploited for numerous refractory or uncontrolled inflammatory conditions by identifying novel targets for functional blockade. Interleukin (IL)-18, a pro-inflammatory cytokine, is relatively underestimated as a therapeutic target, despite accumulated evidence indicating the unique roles of IL-18 in acute and chronic inflammatory conditions, such as macrophage activation syndrome. Herein, we designed a new form of IL-18 blockade, i.e., APB-R3, a long-acting recombinant human IL-18BP linked to human albumin-binding Fab fragment, SL335, for extending half-life. We then explored the pharmacokinetics and pharmacodynamics of APB-R3. In addition to an extended serum half-life, APB-R3 alleviates liver inflammation and splenomegaly in a model of the macrophage activation syndrome induced in IL-18BP knockout mice. Moreover, APB-R3 substantially controlled skin inflammation in a model of atopic dermatitis. Thus, we report APB-R3 as a new potent IL-18 blocking agent that could be applied to treat IL-18-mediated inflammatory diseases.


Asunto(s)
Dermatitis Atópica , Síndrome de Activación Macrofágica , Ratones , Animales , Humanos , Dermatitis Atópica/tratamiento farmacológico , Interleucina-18/uso terapéutico , Albúmina Sérica Humana/uso terapéutico , Síndrome de Activación Macrofágica/tratamiento farmacológico , Citocinas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Inflamación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...